Trial Profile
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Nov 2019
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; KY-1044 (Primary)
- Indications Advanced breast cancer; Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Renal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Kymab
- 04 Jun 2019 Study design was presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 01 Feb 2019 Status changed from planning to recruiting.
- 25 Jul 2018 New trial record